ArticleJournal of translational medicine2005
Adoptive T cell therapy: Addressing challenges in cancer immunotherapy.
Article in Journal of translational medicine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Decoupling T cell cytotoxicity: a CCL21+ICAM1-based synthetic immune niche enhances tumor elimination by accelerating lytic hit delivery.BMC cancer · 2026Article
- Feature Selection Enhances Peptide Binding Predictions for TCR-Specific Interactions.bioRxiv : the preprint server for biology · 2024Article
- Feature selection enhances peptide binding predictions for TCR-specific interactions.Frontiers in immunology · 2024Article
- Quantitative approaches for decoding the specificity of the human T cell repertoire.Frontiers in immunology · 2023Review
- Hybrid gMLP model for interaction prediction of MHC-peptide and TCR.Frontiers in genetics · 2022Article
- NetTCR-2.0 enables accurate prediction of TCR-peptide binding by using paired TCRα and β sequence data.Communications biology · 2021Article
- Semiflexible Immunobrushes Induce Enhanced T Cell Activation and Expansion.ACS applied materials & interfaces · 2021Article
- 'Off-the-shelf' allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies.Journal for immunotherapy of cancer · 2021Article
- Improving Tumor Retention of Effector Cells in Adoptive Cell Transfer Therapies by Magnetic Targeting.Pharmaceutics · 2020Review
- Novel chimeric antigen receptor T cells based on T-cell receptor-like antibodies.Blood science (Baltimore, Md.) · 2019Article
- Magnetic targeting of adoptively transferred tumour-specific nanoparticle-loaded CD8Journal of nanobiotechnology · 2019Article
- T cells loaded with magnetic nanoparticles are retained in peripheral lymph nodes by the application of a magnetic field.Journal of nanobiotechnology · 2019Article
- Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing.Frontiers in immunology · 2019Review
- Genetic Modification of CD8Frontiers in immunology · 2019Article
- Injectable, Tough Alginate Cryogels as Cancer Vaccines.Advanced healthcare materials · 2018Article
- Cell surface engineering and application in cell delivery to heart diseases.Journal of biological engineering · 2018Review
- Expansion and Antitumor Cytotoxicity of T-Cells Are Augmented by Substrate-Bound CCL21 and Intercellular Adhesion Molecule 1.Frontiers in immunology · 2018Article
- Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.Leukemia · 2015Article
- Immunotherapy for the treatment of breast cancer.Current oncology reports · 2015Review
- Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.Immunotherapy · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adoptive T cell therapy involves the ex vivo selection and expansion of effector cells for the treatment of patients with cancer. In this review, the advantages and limitations of using antigen-specific T cells are discussed in counterpoint to vaccine strategies. Although vaccination strategies represent more readily available reagents, adoptive T cell therapy provides highly selected T cells of defined phenotype, specificity and function that may influence their biological behavior in vivo. Adoptive T cell therapy offers not only translational opportunities but also a means to address fundamental issues in the evolving field of cancer immunotherapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.